Introduction
============

Bladder cancer is one of the most common cancer ranking fourth in incidence in Western countries and first in China ([@b1-br-0-0-705],[@b2-br-0-0-705]). There are \~380,000 new cases and 150,000 fatalities per year worldwide ([@b3-br-0-0-705]). Bladder cancer is staged via the tumor-node-metastasis system, which describes the extent of invasion (Tis-T4) ([@b4-br-0-0-705],[@b5-br-0-0-705]). Approximately 75% of patients present with non-invasive bladder cancer (NIBC; stage Ta), but a quarter suffer muscle-invasive bladder cancer (MIBC) at the time of diagnosis (of stage T2 and above) and they have a less favorable prognosis with 5-year survival \<50% ([@b6-br-0-0-705],[@b7-br-0-0-705]). Despite improvements in surgical techniques and postoperative recovery pathways, this complex procedure remains highly challenging, and the treatment has not advanced for several decades ([@b8-br-0-0-705],[@b9-br-0-0-705]). Furthermore, the high cost of surgery and management of subsequent complications, chemotherapy, surveillance imaging and high end-of-life costs contribute to the substantial financial burden of advanced disease ([@b10-br-0-0-705]). Therefore, development of early biological markers for diagnosis of MIBC is of importance.

MicroRNA (miRNA) is endogenous RNA of \~22 nucleotides that targets mRNA for cleavage or translational repression. miRNA families are responsible for a number of physiological processes, including cell growth/differentiation, maintenance of internal environmental stabilization, immune response and embryonic development of different cancers ([@b11-br-0-0-705]--[@b14-br-0-0-705]). Increasing evidence has suggested that miRNAs can be transmitted through extracellular vesicles, such as exosomes, that are devoted to cell-cell contact and influence, and additionally they are convenient for detection ([@b15-br-0-0-705],[@b16-br-0-0-705]). Thus far, various miRNAs have been identified to have prognostic values with bladder cancer, in NIBC and MIBC ([@b17-br-0-0-705]--[@b19-br-0-0-705]).

Currently, there are few meta-analyses published on the diagnostic performance of miRNA assays for MIBC. Therefore, the present study performed a meta-analysis to review and assess the overall diagnostic values of miRNA assays for MIBC.

Materials and methods
=====================

### Publication search

To identify all the potentially eligible studies on miRNA polymorphisms and cancer risk, we carried out a systematic search on PubMed, Web of Science and Chinese National Knowledge Infrastructure, covering all studies published between January 1, 2000 and January 25, 2016, using the search terms: ('miR' or 'miRNAs' or 'microRNAs') and ('diagnostic value' or 'diagnoses' or 'receiver operating characteristics' or 'ROC curve' or 'sensitivity and specificity') and ('muscle-invasive bladder cancer, muscle-invasive urinary bladder neoplasms, muscle-invasive urothelial cancer, MIBC, MIUCC'). References of the retrieved studies and review studies were also screened. Qualified studies had to meet all the following standards: i) Diagnosis of MIBC in histology, ii) utility of miRNA expression profiles (from tissue or blood or urine) for urological cancers diagnosis. The exclusion criteria included: i) Reviews, case reports, and meta analyses, ii) studies not related to MIBC and the diagnostic value of miRNA for urological cancers, iii) studies without valid data.

### Data extraction and quality assessment

Quality assessment was performed for each included study by independent reviewers using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool ([@b20-br-0-0-705]). The QUADAS-2 tool contains seven questions, and each one should be answered with 'yes' (1 score), 'unclear' or 'no' (0 score). All questions were given equal weight, resulting in a maximum possible score of 7. Conflicting evaluation was resolved following a full discussion.

The assessment consisted of four domains: Patient selection, index test, reference standard, and flow and timing. The first three domains were assessed in terms of applicability. Each of the four domains was assessed via the risk of bias. Assessments were labeled as 'high', 'low' or 'unclear', corresponding to high risk, low risk and unclear, respectively.

### Statistical analysis

All the statistical analyses were performed using Rev Man 5.3 software (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). The sensitivity and specificity data of miRNAs associated with the predicted and/or diagnostic value of MIBC were extracted from each study. First, the results of sensitivity, specificity, positive and negative likelihood ratio (PLR and NLR, respectively), diagnostic odds ratio (DOR) and 95% confidence intervals (CIs) were calculated using the random-effect model. Subsequently, the summary receiver operator characteristic (SROC) curve was created and the area under the SROC curve (AUC) was calculated. PLR was on behalf of the odds of positive test results of MIBC patients, while NLR reflected the odds of positive results in those without MIBC. DOR was the outcome of the combination of PLR and NLR (DOR = PLR/NLR). In addition, the heterogeneity between studies was evaluated through χ^2^ test and I^2^ test. If the tests show a P\<0.1 or I^2^\>50%, the existence of significant heterogeneity would be verified ([@b21-br-0-0-705]). Subsequently, meta-regression and subgroup analyses were undertaken to explore the sources of between-study heterogeneity. Furthermore, Deeks\' funnel plots were adopted to evaluate the publication bias.

The percentages of patients in each subgroup were calculated for the categorical variables using unpaired Student\'s t-test, χ^2^ test or Fisher\'s exact test, appropriately.

Results
=======

### Patient characteristics

The flow graph of study selections is shown in [Fig. 1](#f1-br-0-0-705){ref-type="fig"}. A total of 125 potentially relevant studies were selected with an established search strategy. Following a detailed evaluation, 10 studies ([@b22-br-0-0-705]--[@b31-br-0-0-705]) were used for the meta-analysis. The main characteristics of the included studies are summarized in [Table I](#tI-br-0-0-705){ref-type="table"}. Among the 10 studies, the total number of patients and controls were 577 and 412, respectively. Four studies were conducted in Asian populations, while the remaining studies were conducted in Caucasian populations. The diagnostic performances of single and multiple miRNAs have been investigated among those included studies.

### Quality assessment of studies

The results of the QUADAS-2 assessment are shown as a bar graph in [Fig. 2](#f2-br-0-0-705){ref-type="fig"}. The majority of all included studies fulfilled the majority of the items in QUADAS-2, which indicated that the general quality of the included studies is good.

### Diagnostic accuracy

Due to the existence of significant heterogeneity between studies in sensitivity and specificity (I^2^=81.3% and I^2^=77.8%), the random effects model was adopted. [Fig. 3](#f3-br-0-0-705){ref-type="fig"} depicts the forest plots of data from the miRNA panels subgroup and mean sensitivity and specificity. The pooled results of diagnostic criteria and their 95% CIs are listed in [Table II](#tII-br-0-0-705){ref-type="table"}. The overall sensitivity, specificity, PLR, NLR and DOR were 0.78 (0.69--0.86), 0.77 (0.72--0.81), 2.9 (95% CI, 2.1--3.8), 0.31 (95% CI, 0.27--0.35), 7 (95% CI, 4--13), respectively. Moreover, the SROC curve was generated and the AUC was calculated as 0.80 (95% CI, 0.69--0.87) ([Fig. 4](#f4-br-0-0-705){ref-type="fig"}), which implied a relatively high diagnostic accuracy.

### Subgroup analyses

A subgroup analyses was also performed to identify potential sources of heterogeneity ([Table II](#tII-br-0-0-705){ref-type="table"}). For single miRNA profiling assays, sensitivity, specificity and AUC values were 0.70 (0.65--0.74), 0.73 (95% CI, 0.67--0.79), and 0.79 (95% CI, 0.76--0.82), respectively. For multiple miRNAs, the sensitivity (SEN), specificity (SPE) and AUC values were 0.81 (95% CI, 0.72--0.91), 0.84 (95% CI, 0.75--0.93) and 0.86 (95% CI, 0.83--0.89), respectively. These data indicated that multiple miRNAs profiling were more accurate than single miRNA profiling. The studies based on Caucasian populations had a pooled sensitivity of 0.71 and a specificity of 0.76, while studies based on Asian populations had a relatively lower sensitivity (0.67) and specificity (0.75). The subgroup analyses suggested that the ethnicity and miRNA profiling had an evident influence on the diagnostic accuracy. Therefore, these factors may be the potential sources of heterogeneity.

### Publication bias

Finally, the Deeks\' funnel plot asymmetry test was conducted to evaluate the publication bias. The P-value of 0.7 suggested that no significant publication bias existed among the studies ([Fig. 5](#f5-br-0-0-705){ref-type="fig"}).

Discussion
==========

Although clear progression in surgery and chemical treatment has been achieved in MIBC, the prognosis of the patients is poor ([@b6-br-0-0-705],[@b7-br-0-0-705]). As aforementioned, approximately a quarter of bladder cancer patients have MIBC at diagnosis, and the critical factor is how to detect and diagnose MIBC as early as possible. Thus, novel and reliable biomarkers for MIBC detection are urgently required.

As the existing biomarkers do not exhibit high sensitivity and specificity in MIBC detection, miRNAs have been reported as markers of MIBC in numerous studies. Pignot *et al* ([@b23-br-0-0-705]) reported that miR-9, miR-182 and miR-200b were associated with MIBC aggressiveness, and with recurrence-free and overall survival in univariate analysis and multivariate analysis. Avgeris *et al* ([@b28-br-0-0-705]) reported that high miR-143/145 levels could predict the inferior overall survival for MIBC effectively and the progression of superficial tumors independently. Xu *et al* ([@b30-br-0-0-705]) identified four specific miRNAs (let-7c, mir-125b-1, mir-193a, and mir-99a) in association with the progression and aggressiveness of MIBC via microarray analysis. Several genome-wide profiling studies have been reported and identified specific miRNA alterations in bladder cancer ([@b32-br-0-0-705]--[@b34-br-0-0-705]). Those results suggested a promising prognostic value of these miRNAs markers.

However, as the association between miRNAs and MIBC are inconsistent and the studies are designed differently, comparing the wide ranges of diagnostic performance is difficult. Therefore, the present study aimed to summarize the result of individual studies and investigate the diagnostic value of miRNAs for MIBC.

Following analysis, the overall sensitivity and specificity of miRNAs was 0.78 and 0.77, which indicated accuracy of miRNAs to detect MIBC. The pooled PLR was 2.9 and the pooled NLR was 0.31, respectively. The AUC was 0.80 and DOR was 7. These data suggested that miRNAs had a relatively high diagnostic accuracy. As heterogeneity between studies could affect the results of the meta-analysis, subgroup analyses will aid to understand these influences. Therefore, subgroup analyses were performed based on ethnicity and miRNA profiling. Subgroups of miRNA profiling indicated that multiple miRNA assays (SEN, SPE and AUC of 0.81, 0.84 and 0.86, respectively) had a higher diagnostic performance than those of single miRNA assays (SEN, SPE and AUC of 0.70, 0.73 and 0.79, respectively). No significant different was observed for the miRNA expression profile test between the Asian and Caucasian groups.

There were several limitations in the meta-analysis. First, the included studies were based on limited sample size, and if the specimen of miRNA could be divided into blood, urine, tissue groups, do analysis and comparison respectively, the results may be more significant and accurate. Second, the majority of the included studies did not differentiate the grade of MIBC, and therefore, subgroup analyses based on these variables were restricted due to limited reported data. Third, as the majority of the studies did not provide further miRNA research, the changes of miRNA in different stages of MIBC, following treatment in different methods or in patients who received treatment experiencing MIBC again could not be verified.

In conclusion, the present study analyzed the pooled data of SEN, SPE, PLR, NLR, DOR and AUC from 10 studies. miRNA assays could serve as markers for MIBC diagnosis, particularly the combined usage of miRNA, and have a good potential as an accurate biomarker to diagnose of MIBC. However, the clinical application of miRNA profiling for MIBC diagnosis remains validating in future studies.

MIBC

:   muscle-invasive bladder cancer

NIBC

:   non-invasive bladder cancer

PLR

:   positive likelihood ratio

NLR

:   negative likelihood ratio

DOR

:   diagnostic odds ratio

SROC

:   summary receiver operator characteristic

SEN

:   sensitivity

SPE

:   specificity

AUC

:   area under SROC curve

![Flow chart of the included studies.](br-05-02-0159-g00){#f1-br-0-0-705}

![General assessment quality of the included studies using the Quality Assessment of Diagnostic Accuracy Studies-2 tool.](br-05-02-0159-g01){#f2-br-0-0-705}

![Forest plots of (A) sensitivity and (B) specificity of miRNAs for the miRNA panel subgroups. CI, confidence interval.](br-05-02-0159-g02){#f3-br-0-0-705}

![SROC curve of the studies with confidence and prediction region around mean operating sensitivity and specificity. SROC, summary receiver operator characteristic.](br-05-02-0159-g03){#f4-br-0-0-705}

![Deeks\' linear regression test of funnel plot asymmetry. ESS, effective sample size.](br-05-02-0159-g04){#f5-br-0-0-705}

###### 

Main characteristics of the 10 studies included in the meta-analysis.

                                         Sample size, n   Mean age, year   Mean ratio, %                                                                                                   
  --------------- ---------- ----------- ---------------- ---------------- --------------- ---- ------ -------- --------------- -------- -------------------------------------- ------ --- ---------------------
  Veerla, 2009    Sweden     Caucasian     17               17             NA              NA   NA     NA       Normal          Tissue   miR-100, miR-125b, miR-199b, miR-222   Up     5   ([@b22-br-0-0-705])
  Pignot, 2012    France     Caucasian     80               11             70              67   78.8     79.5   Normal          Tissue   miR-9, miR-182, miR-200b               Up     7   ([@b23-br-0-0-705])
                                                                                                                                         miR-1, miR-133a, miR-133b              Down       
                                                                                                                                         miR-143, miR-145, miR-204              Down       
                                                                                                                                         miR-199a, miR-199b, miR-1281           Down       
  Pignot, 2012      France   Caucasian     21               5              68              66   90.5   100.0    Normal          Tissue   miR-19A, miR-20A, miR-92A              Up     6   ([@b24-br-0-0-705])
  Adam, 2013      Germany    Caucasian     10               18             62              55   70.0     46.0   Normal          Blood    miR-200b, miR-541, miR-566             Up     7   ([@b25-br-0-0-705])
                                                                                                                                         miR-543, miR-544,                      Up         
                                                                                                                                         miR-604, miR-940-p                                
                                                                                                                                         miR-33b, miR-92b,6                     Down       
                                                                                                                                         miR-1246, miR-182                                 
                                                                                                                                         miR-25, miR-148b, miR-487              Down       
  Ratert, 2013    Germany    Caucasian     15               42             74              68   80.0     83.0   NMIBC, normal            miR-141, miR-205                       Up     6   ([@b26-br-0-0-705])
  Li, 2014        China      Asian         15               15             NA              NA   NA     NA       Normal          Tissue   miR-34a                                Up     5   ([@b27-br-0-0-705])
  Avgeris, 2015   Greece     Caucasian     45               39             NA              NA   84.3   NA       Normal          Tissue   miR-143, miR-145, miR-224              Up     5   ([@b28-br-0-0-705])
  Wang, 2015      China      Asian       144              169              NA              NA   68.2   NA       Normal          Urine    miR-124                                Up     6   ([@b29-br-0-0-705])
  Xu, 2015        China      Asian       202                40             68              64   74.3     65.0   Normal          Tissue   let-7c, mir-125b-1                     Up     7   ([@b30-br-0-0-705])
                                                                                                                                         mir-193a, mir-99a                      Up         
  Fang, 2015      China      Asian         28               56             75              74   71.4     64.2   Normal          Tissue   mir-205                                Up     6   ([@b31-br-0-0-705])

miRNA, microRNA; NA, not available; NMIBC, non-muscle invasive bladder cancer.

###### 

Summary estimates of diagnostic criteria and the 95% confidence intervals (CIs).

  Analysis           Sensitivity (95% CI)   Specificity (95% CI)   PLR (95% CI)     NLR (95% CI)        DOR (95% CI)                                AUC (95% CI)
  ------------------ ---------------------- ---------------------- ---------------- ------------------- ------------------------------------------- -------------------
  Ethnicity                                                                                                                                         
    Caucasian        0.71 (0.66--0.75)      0.76 (0.67--0.83)      2.4 (2.0--2.8)   0.34 (0.22--0.46)     6 ([@b4-br-0-0-705]--[@b11-br-0-0-705])   0.74 (0.69--0.78)
    Asian            0.67 (0.63--0.72)      0.75 (0.73--0.82)      2.5 (2.1--3.0)   0.32 (0.21--0.42)     7 ([@b5-br-0-0-705]--[@b12-br-0-0-705])   0.82 (0.77--0.86)
  miRNA profiling                                                                                                                                   
    Single miRNA     0.70 (0.65--0.74)      0.73 (0.67--0.79)      2.6 (2.3--2.9)   0.38 (0.29--0.47)     5 ([@b3-br-0-0-705]--[@b10-br-0-0-705])   0.79 (0.76--0.82)
    Multiple miRNA   0.81 (0.72--0.91)      0.84 (0.75--0.93)      4.2 (2.7--5.7)   0.26 (0.15--0.37)   16 ([@b9-br-0-0-705]--[@b24-br-0-0-705])    0.86 (0.83--0.89)
  Overall            0.78 (0.69--0.86)      0.77 (0.72--0.81)      2.9 (2.1--3.8)   0.31 (0.27--0.35)     7 ([@b4-br-0-0-705]--[@b13-br-0-0-705])   0.80 (0.69--0.87)

PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, area under the curve; miRNA, microRNA.
